Last reviewed · How we verify
Biological tests
Biological tests refer to laboratory diagnostic procedures that measure biological markers, analytes, or cellular/molecular parameters to assess health status, disease presence, or treatment response.
Biological tests refer to laboratory diagnostic procedures that measure biological markers, analytes, or cellular/molecular parameters to assess health status, disease presence, or treatment response. Used for Clinical laboratory diagnosis and monitoring (non-specific; used across all medical conditions).
At a glance
| Generic name | Biological tests |
|---|---|
| Sponsor | Centre Hospitalier Universitaire de Saint Etienne |
| Modality | Biologic |
| Therapeutic area | Diagnostics |
| Phase | FDA-approved |
Mechanism of action
Biological tests encompass a broad category of in vitro diagnostic assays performed on patient samples (blood, urine, tissue, etc.) to quantify or detect biomarkers, pathogens, or physiological parameters. These tests support clinical decision-making by providing objective data on disease state, organ function, or therapeutic efficacy. They are foundational to modern medical practice across all therapeutic areas.
Approved indications
- Clinical laboratory diagnosis and monitoring (non-specific; used across all medical conditions)
Common side effects
Key clinical trials
- Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer (PHASE2)
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial (PHASE1)
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors (PHASE1)
- Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A) (PHASE2)
- Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma (PHASE1)
- Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Biological tests CI brief — competitive landscape report
- Biological tests updates RSS · CI watch RSS
- Centre Hospitalier Universitaire de Saint Etienne portfolio CI